Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sciele Pharma has announced that Addrenex Pharmaceuticals has completed patient enrollment of its first Phase III clinical trial in the US for Clonicel to treat attention deficit and hyperactivity disorder in children.
Subscribe to our email newsletter
Addrenex is also continuing to enroll patients in an additional Phase III trial using Clonicel in combination with stimulants such as methylphenidate and dextro-amphetamine/amphetamine to treat attention deficit and hyperactivity disorder (ADHD).
In July 2007, Sciele signed an exclusive licensing agreement with Addrenex to market a sustained-release formulation of clonidine hydrochloride for the treatment of ADHD and hypertension.
Moise Khayrallah, CEO of Addrenex, said: “Our goal is to provide another option for patients who need an alternative to stimulants or who may benefit from combination therapy using Clonicel together with other approved ADHD medications.”